Provider Briefing: Buspirone Availability in 2026

Buspirone remains a cornerstone of non-benzodiazepine anxiolytic therapy, particularly for generalized anxiety disorder (GAD) and as an adjunctive agent in depression management. Its favorable side effect profile, absence of abuse potential, and status as a non-controlled substance make it a preferred first-line option across primary care, psychiatry, and behavioral health settings.

However, providers should be aware that while Buspirone is not currently on a national shortage list, patients frequently report difficulty filling prescriptions at retail pharmacies. This briefing covers the current supply picture, prescribing considerations, cost landscape, and practical tools to support patient access.

Shortage Timeline

Understanding Buspirone's supply history provides useful context for current availability issues:

• 2001: BuSpar patent expires; multiple generic manufacturers enter the market, significantly reducing cost and expanding access.
• 2010: Brand-name BuSpar discontinued by Bristol-Myers Squibb — not for safety reasons, but due to the mature generic market. The FDA confirmed it was not withdrawn for efficacy or safety concerns.
• 2019: Significant supply disruption as several generic manufacturers experienced production issues. The ASHP and FDA listed Buspirone as in shortage. Supply chain problems intersected with rising demand for non-benzodiazepine anxiolytics, creating a challenging period for prescribers and patients alike.
• 2020-2024: Supply gradually stabilized as manufacturers resumed full production. Spot shortages continued intermittently, particularly for less common strengths (7.5 mg, 30 mg).
• 2025-2026: Buspirone is not on the FDA Drug Shortages list as of March 2026. National supply appears adequate, though localized stock-outs persist. Multiple generic manufacturers (Teva, Mylan/Viatris, Aurobindo, Amneal, and others) are actively producing.

Prescribing Implications

The intermittent availability issues with Buspirone have several practical implications for prescribers:

Dosage Strength Selection

Not all pharmacies stock all five available strengths (5 mg, 7.5 mg, 10 mg, 15 mg, 30 mg). The 5 mg and 10 mg tablets are the most universally stocked. When possible, consider prescribing in these strengths to maximize the likelihood that patients can fill without delays. For example, prescribing two 5 mg tablets BID instead of one 10 mg tablet BID doesn't change the clinical outcome but gives patients a fallback if 10 mg tablets are unavailable.

Onset and Patient Expectations

Buspirone requires 2-4 weeks for therapeutic effect. Patients who experience a gap in supply may become anxious about restarting — and anxious about their anxiety returning in the interim. Setting expectations upfront about this timeline, and having a contingency plan for supply interruptions, can improve adherence and patient satisfaction.

Serotonin Syndrome Vigilance

Buspirone is frequently used alongside SSRIs and SNRIs. While the serotonin syndrome risk with Buspirone alone is low, the combination increases risk — particularly if patients self-adjust doses during supply gaps or inadvertently overlap with stockpiled medication. Counsel patients against dose manipulation and ensure they understand critical drug interactions.

Telehealth Prescribing

Buspirone's non-controlled status makes it well-suited for telehealth prescribing. Providers offering virtual care can prescribe Buspirone without the regulatory constraints applied to scheduled substances. This is particularly beneficial for patients in rural or underserved areas with limited pharmacy options.

Current Availability Picture

While no formal shortage exists, providers should be aware of the patterns behind patient access difficulties:

• Chain pharmacies (CVS, Walgreens, Rite Aid) maintain automated inventory systems that may not restock less-demanded strengths until a threshold is met, leading to temporary gaps.
• Independent pharmacies often have more flexibility to source from multiple wholesalers and may be more responsive to patient needs.
• Mail-order pharmacies tend to have the most consistent supply and can offer 90-day fills, reducing the frequency of access issues.
• Regional variation exists — some markets experience more frequent spot shortages than others depending on local prescribing patterns and wholesaler distribution routes.

Providers can direct patients to Medfinder for Providers to help identify pharmacies with current Buspirone stock in their patients' areas.

Cost and Access Landscape

Buspirone remains highly affordable, which supports prescribing for cost-sensitive patient populations:

• Generic cash price: $20-$46 for 60 tablets (30-day supply at standard BID dosing)
• With discount programs: $4-$10 per fill through GoodRx, SingleCare, RxSaver
• Insurance coverage: Covered on most formularies as a Tier 1 generic; typical copay $0-$15
• Walmart $4 program / Costco: Often included in generic discount programs
• No prior authorization required at most plans — a significant advantage over some alternative anxiolytics

For patients facing financial barriers, there is no manufacturer savings program (since BuSpar is discontinued), but resources like NeedyMeds, RxAssist, and state pharmaceutical assistance programs can help. A detailed patient resource is available at: How to Save Money on Buspirone.

Tools and Resources for Providers

Several tools can streamline the process of helping patients access Buspirone:

• Medfinder for Providers: Check real-time pharmacy stock for Buspirone by location. Useful for directing patients to pharmacies that currently have their medication available.
• FDA Drug Shortages Database: Monitor the official shortage status at fda.gov/drugs/drug-shortages.
• ASHP Drug Shortages Resource Center: Additional shortage tracking and management recommendations at ashp.org/drug-shortages.
• Electronic prescribing: E-prescribing to a specific pharmacy with confirmed stock reduces the chance of a patient arriving to an empty shelf.

Alternative Agents When Buspirone Is Unavailable

When supply disruptions prevent patients from accessing Buspirone, consider these alternatives based on the patient's clinical profile:

• Hydroxyzine (Vistaril): Non-controlled antihistamine anxiolytic. Faster onset but more sedating. Good short-term bridge option.
• SSRI adjustment: If the patient is already on an SSRI, dose optimization may partially compensate for the loss of Buspirone's augmenting effect.
• Venlafaxine (Effexor XR): SNRI with FDA approval for GAD. Consider for patients with comorbid depression.
• Pregabalin (Lyrica): Off-label for GAD in the US (approved in EU). Schedule V; good for patients who haven't responded to serotonergic agents.

A patient-facing guide to these options is available: Alternatives to Buspirone.

Looking Ahead

Buspirone's role in anxiety management continues to grow as the medical community moves away from long-term benzodiazepine use. The combination of efficacy, safety, affordability, and non-controlled status positions it as a foundational anxiolytic for the foreseeable future.

The primary challenge remains supply chain resilience for generic medications with thin profit margins. Providers play a key role in helping patients navigate availability gaps — by prescribing commonly stocked strengths, utilizing pharmacy stock tools, setting realistic expectations about onset time, and having a documented alternative plan in the chart.

Final Thoughts

While the formal shortage picture for Buspirone looks favorable in 2026, the lived experience for many patients involves periodic difficulty filling prescriptions. Proactive prescribing practices, patient education about refill timing, and awareness of stock-checking tools like Medfinder can meaningfully reduce the burden on both providers and patients.

For additional clinical context, see our companion articles: How to Help Your Patients Find Buspirone in Stock and How to Help Patients Save Money on Buspirone.